Enclomiphene
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
A SERM (selective estrogen receptor modulator) — specifically the trans isomer of clomiphene citrate. Clomid (clomiphene citrate) is a 50/50 mix of two isomers: enclomiphene (the trans isomer, anti-estrogenic at the HPG estrogen receptors) and zuclomiphene (the cis isomer, estrogenic and long-acting, source of most of Clomid’s side effects). Pure enclomiphene is effectively “clean Clomid” — the active half without the slow-clearing estrogenic baggage.
Zero testosterone in the molecule. Enclomiphene is not an androgen, not a steroid, not a hormone. It’s a competitive antagonist that blocks estradiol from binding to its HPG receptors.
What does it do in my body?
- Higher affinity for hypothalamic + pituitary estrogen receptors than estradiol itself.
- Physically blocks estradiol from binding → brain interprets the blocked signal as “catastrophic hypoestrogenism emergency.”
- GnRH pulse amplitude and frequency crank up dramatically.
- Pituitary gonadotrophs hypersensitize → tsunami of LH + FSH.
- LH flood → Leydig cells max out T production to the individual’s genetic ceiling (you cannot overdrive what your factory is capable of).
- FSH surge → Sertoli cells dramatically increase spermatogenesis.
How can it help me?
- Best fit: Low T + low or inappropriately normal LH (secondary hypogonadism), especially when fertility preservation matters
- Where the science stands: Established SERM mechanism (same class as Clomid); strongest indication is male fertility; the same mechanism is FDA-approved for ovulation induction in women
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
- Generally clean compared to clomiphene citrate (the zuclomiphene component carries most of the Clomid side-effect load).
- Possible: mood changes, headaches, visual disturbances (rare, classically associated with high-dose clomiphene).
- Vision changes that don’t resolve = stop and re-evaluate.
- SHBG elevation may require free T monitoring to assess whether the protocol is actually delivering bioavailable testosterone. Total T alone is an insufficient readout.
Regulatory status: Not currently FDA-approved for male hypogonadism in the US — used off-label. Clomiphene citrate (Clomid) is approved for female infertility. Pure enclomiphene was pursued by Repros Therapeutics; a New Drug Application was filed but development hit regulatory headwinds.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
- Form: oral pill (the only non-injectable HPGA-restoration lever).
- Community dose for male hypogonadism: 12.5–25 mg/day, often dosed daily; some users do EOD (every other day).
- Cycle: continuous use is common; some users cycle 12 weeks on / 4 weeks off to assess HPG function without enclomiphene support.
- Blood work to track: Total T, free T, LH, FSH, estradiol, SHBG. Baseline + 6–8 weeks + 12 weeks.
What should I avoid combining — and what's synergistic?
Enclomiphene doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Wiki article (split 2026-07-16 from the retired HPGA-restoration cluster article, per-compound doctrine). Built from. Cross-links: HCG (Human Chorionic Gonadotropin) · Gonadorelin · Kisspeptin · Ipamorelin · CJC-1295 / Ipamorelin. The broader “which lever matches your bloodwork” decision framework — the HPG-axis mechanism map, the decision algorithm, and the TRT-vs-restoration big picture — now lives in the Peptides 101 article HPGA Restoration: Choosing the Right Lever.
| Class | SERM (selective estrogen receptor modulator) — the trans isomer of clomiphene citrate |
| Mechanism (one line) | Higher affinity than estradiol for hypothalamic + pituitary estrogen receptors → physically blocks estradiol from binding → brain reads “hypoestrogenism emergency” → GnRH pulse amplitude/frequency crank up → LH + FSH surge → native testosterone and sperm production rise |
| Acts at | Estrogen feedback receptors in the hypothalamus + pituitary (downstream of Gonadorelin/Kisspeptin, upstream of HCG in the HPG cascade) |
| Route / frequency | Oral pill — the only non-injectable of the HPGA-restoration levers; 12.5–25 mg/day, some EOD |
| Best-fit use case | Low T + low or inappropriately normal LH (secondary hypogonadism), especially when fertility preservation matters |
| Evidence base | Established SERM mechanism (same class as Clomid); strongest indication is male fertility; the same mechanism is FDA-approved for ovulation induction in women |
| Regulatory status | Not FDA-approved for male hypogonadism (used off-label); Clomiphene citrate (Clomid) is FDA-approved for female infertility |
What it is
A SERM (selective estrogen receptor modulator) — specifically the trans isomer of clomiphene citrate. Clomid (clomiphene citrate) is a 50/50 mix of two isomers: enclomiphene (the trans isomer, anti-estrogenic at the HPG estrogen receptors) and zuclomiphene (the cis isomer, estrogenic and long-acting, source of most of Clomid’s side effects). Pure enclomiphene is effectively “clean Clomid” — the active half without the slow-clearing estrogenic baggage.
Zero testosterone in the molecule. Enclomiphene is not an androgen, not a steroid, not a hormone. It’s a competitive antagonist that blocks estradiol from binding to its HPG receptors.
How it works
- Higher affinity for hypothalamic + pituitary estrogen receptors than estradiol itself.
- Physically blocks estradiol from binding → brain interprets the blocked signal as “catastrophic hypoestrogenism emergency.”
- GnRH pulse amplitude and frequency crank up dramatically.
- Pituitary gonadotrophs hypersensitize → tsunami of LH + FSH.
- LH flood → Leydig cells max out T production to the individual’s genetic ceiling (you cannot overdrive what your factory is capable of).
- FSH surge → Sertoli cells dramatically increase spermatogenesis.
What the research shows
- The strongest indication is male fertility. Enclomiphene is the only tool that simultaneously elevates testosterone and enhances sperm production via FSH — neither TRT nor HCG does both. Many male-infertility cases routed to costly IVF have not been tested on enclomiphene first.
- LH/FSH surge magnitudes in male hypogonadism trials.
- In women, the same SERM mechanism is FDA-approved as the original Clomid indication — ovulation induction for fertility (blocks midcycle estrogen feedback → triggers FSH + LH surge).
Why enclomiphene and TRT feel different at the same total testosterone number
A common clinical experience: a man switches from TRT to enclomiphene, achieves the same or higher total testosterone on labs, but feels noticeably worse. Two interlocking mechanics explain this.
1. SHBG directionality (the binding globulin mechanic):
- TRT lowers SHBG. Exogenous testosterone appears to signal reductions in hepatic SHBG production. Lower SHBG → more testosterone stays free (unbound) → available to reach androgen receptors on cells.
- Enclomiphene raises SHBG. The estrogenic / SERM-stimulation environment increases hepatic SHBG output. Higher SHBG → more of the newly elevated testosterone gets bound and rendered inactive → lower free T despite normal or high total T.
- Net effect: at identical total T, the enclomiphene user has meaningfully less free T actually reaching muscle, brain, and receptor sites. The lab looks fine; the subjective experience doesn’t match.
- Compounding factor: poor lifestyle (insulin resistance, excess body fat, poor sleep, sedentary status) also independently elevates SHBG. An enclomiphene user with lifestyle dysfunction gets a double SHBG hit — the molecule plus the environment. This is why enclomiphene often underdelivers for men who haven’t addressed the lifestyle root cause first.
2. DHT conversion delta:
- Exogenous testosterone (TRT) freely converts to DHT (via 5-alpha reductase) both systemically and locally within brain tissue.
- DHT drives meaningful improvements in gym drive, aggression, mental clarity, and libido — effects many users attribute to “testosterone” but are actually DHT downstream.
- Enclomiphene-stimulated endogenous testosterone: a portion of the total T gets bound by elevated SHBG before it can reach 5-alpha reductase → less free substrate for DHT conversion → less DHT at target tissues.
- The TRT user gets elevated free T and elevated DHT. The enclomiphene user at the same total T gets less of both.
Clinical implication: Total testosterone is an incomplete readout when comparing these two approaches. The full panel — total T, free T, SHBG, E2, DHT, LH, FSH — tells the real story. When a patient on enclomiphene has great total T but feels flat, free T and SHBG are the first things to check.
Decision framing (Holyfield / Apex Medical Group): Enclomiphene is best positioned as a temporary bridge for lifestyle-driven secondary hypogonadism — give the patient enough testosterone signal to get in the gym and correct the lifestyle factors that raised SHBG in the first place. Once lifestyle is dialed (weight lost, training consistent, sleep fixed), testosterone often normalizes and enclomiphene can be discontinued. For men with primary hypogonadism or men whose lifestyle is already optimized and testosterone remains low, TRT is the mechanistically appropriate tool because the native-stimulation loop enclomiphene relies on is either broken or already working as well as it can.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
- Form: oral pill (the only non-injectable HPGA-restoration lever).
- Community dose for male hypogonadism: 12.5–25 mg/day, often dosed daily; some users do EOD (every other day).
- Cycle: continuous use is common; some users cycle 12 weeks on / 4 weeks off to assess HPG function without enclomiphene support.
- Blood work to track: Total T, free T, LH, FSH, estradiol, SHBG. Baseline + 6–8 weeks + 12 weeks.
Side effects & management
- Generally clean compared to clomiphene citrate (the zuclomiphene component carries most of the Clomid side-effect load).
- Possible: mood changes, headaches, visual disturbances (rare, classically associated with high-dose clomiphene).
- Vision changes that don’t resolve = stop and re-evaluate.
- SHBG elevation may require free T monitoring to assess whether the protocol is actually delivering bioavailable testosterone. Total T alone is an insufficient readout.
Regulatory status
Not currently FDA-approved for male hypogonadism in the US — used off-label. Clomiphene citrate (Clomid) is approved for female infertility. Pure enclomiphene was pursued by Repros Therapeutics; a New Drug Application was filed but development hit regulatory headwinds.
Sources
- the TRT-vs-Enclomiphene mechanism contrast, HPG axis mechanism map, decision algorithm, the strongest-indication-is-fertility claim.
- Established endocrinology: HPG axis cascade, SERM mechanism, primary vs. secondary hypogonadism distinction.
Related: HCG (Human Chorionic Gonadotropin) · Gonadorelin · Kisspeptin · Ipamorelin · CJC-1295 / Ipamorelin.
Sources & references
- the TRT-vs-Enclomiphene mechanism contrast, HPG axis mechanism map, decision algorithm, the strongest-indication-is-fertility claim.
- Established endocrinology: HPG axis cascade, SERM mechanism, primary vs. secondary hypogonadism distinction.
Related: HCG (Human Chorionic Gonadotropin) · Gonadorelin · Kisspeptin · Ipamorelin · CJC-1295 / Ipamorelin.